Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $80.8500 (0.26%) ($79.5100 - $81.2900) on Tue. Mar. 19, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.87% (three month average) | RSI | 57 | Latest Price | $80.8500(0.26%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 0.5% a day on average for past five trading days. | Weekly Trend | ABBV advances 0.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(60%) VYM(50%) DIA(49%) IVE(49%) SPLV(49%) | Factors Impacting ABBV price | ABBV will decline at least -0.935% in a week (0% probabilities). TLT(-15%) UUP(-13%) VXX(-12%) VIXM(-11%) IFRA(-10%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.935% (StdDev 1.87%) | Hourly BBV | 0 () | Intraday Trend | 0.6% | | | |
|
5 Day Moving Average | $80.35(0.62%) | 10 Day Moving Average | $79.32(1.93%) | 20 Day Moving Average | $79.46(1.75%) | To recent high | -11.2% | To recent low | 4.8% | Market Cap | $142.642b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |